Objective: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD. Conclusions: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.
Treatments used for obsessive-compulsive disorder-an international perspective / Brakoulias, Vlasios; Starcevic, Vladan; Albert, Umberto; Arumugham, Shyam Sundar; Bailey, Brenda E.; Belloch, Amparo; Borda, Tania; Dell'Osso, Liliana; Elias, Jason A.; Falkenstein, Martha J.; Ferrao, Ygor A.; Fontenelle, Leonardo F.; Jelinek, Lena; Kalogeraki, Leto; Kay, Brian; Laurito, Luana D.; Lochner, Christine; Maina, Giuseppe; Marazziti, Donatella; Martin, Andrew; Matsunaga, Hisato; Miguel, Euripedes C.; Morgado, Pedro; Mourikis, Irakis; Pasquini, Massimo; Perez Rivera, Rodrigo; Potluri, Sriramya; Reddy, Janardhan Y. C.; Riemann, Brian C.; do Rosario, Maria Conceição; Shavitt, Roseli G.; Stein, Dan J.; Viswasam, Kirupumani; Wang, Zhen; Fineberg, Naomi A.. - In: HUMAN PSYCHOPHARMACOLOGY. - ISSN 0885-6222. - 34:1(2019), pp. 1-10. [10.1002/hup.2686]
Treatments used for obsessive-compulsive disorder-an international perspective
Pasquini, Massimo;
2019
Abstract
Objective: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD. Conclusions: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.| File | Dimensione | Formato | |
|---|---|---|---|
|
Brakoulias_treatments-used-for-obsessive-compulsive-disorder-an-international-perspective_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
283.83 kB
Formato
Adobe PDF
|
283.83 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
